FLAG Therapeutics is an oncology company developing dual-acting small molecules to efficiently target and kill cancer cells. FLAG has licensed 2 classes of small molecules from Duquesne University (Pgh, PA): AA/AT compounds which are both anti-angiogenic and antitubulin; and FTAC compounds, which are cytotoxic but only taken up by a novel receptor that only sits on certain cancer cells. FLAG has 42 issued + 41 pending patents from Duquesne.